Jump to content
RemedySpot.com

Effects of silybum marianum on patients with chronic hepatitis C

Rate this topic


Guest guest

Recommended Posts

Guest guest

http://journals.mui.ac.ir/jrms/article/view/6551

Journal of Research in Medical Sciences, Vol 16, No 3 (2011)

Home > Vol 16, No 3 (2011) > Kalantari

Effects of silybum marianum on patients with chronic hepatitis C

Hamid Kalantari, Zahra Shahshahan, Mehdi Hejazi, Taghi Ghafghazi, Vahid

Sebghatolahi

Abstract

•BACKGROUND: Silymarin derived from silybum marianum (milk thistle), a flowering

member of the daisy family, may benefit liver function in people infected with

the hepatitis C virus. The aims of this pilot study were to assess the efficacy

and safety of silymarin on serum hepatitis C virus (HCV) RNA, serum

aminotransferases (ALT, AST) levels, liver fibrosis and well-being in patients

with chronic hepatitis C (CHC).

•METHODS: This prospective self-controlled trial study was conducted from March

to September 2006 at Department of Gastroenterology, Isfahan University of

Medical Sciences, Isfahan, Iran. 55 patients with HCV (10 female and 45 male)

with a mean age of 31.8 ± 6.4 years (10-67 years) were participated in the

study. Patients received 24 weeks of silymarin (630 mg/day). Baseline

virological biochemical, liver fibrosis (by a serum fibrosis markers, including

YKL–40 and Hyaluronic acid), and SF-36 questionnaire were performed with

biochemical tests repeated at the end of the treatment period.

•RESULTS: There was statistically difference in mean of ALT (108.7 ± 86.6 vs

70.3 ± 57.7) before and after the treatment (p < 0.001). The means of AST were

99.4 ± 139.7 and 59.7 ± 64.32 before and after the treatment with statistically

differences (p = 0.004). After the treatment, nine patients were found with

negative HCV-RNA (p = 0.004) and statistically significant improvement in

results of liver fibrosis markers were found only in fibrosis group (p = 0.015).

Quality of life was improved significantly (p < 0.001).

•CONCLUSIONS: This study indicated that in patients with CHC performing

silymarin (650 mg/day) for 6 months, improved serum HCV-RNA titer, serum

aminotransferases (ALT, AST), hepatic fibrosis and patient’s quality of life.

More future studies are warranted.

---------------------------------------------------

Full Text: PDF

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...